Unraveling the molecular targets of natural products: Insights from genomic and proteomic analyses

Proteomics - Clinical Applications

Volumn 2, Issue 3, 2008, Pages 338-354

  Wong, Chi Chun ^a   Cheng, Ka Wing ^a   He, Qing Yu ^b   Chen, Feng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b JINAN UNIVERSITY   (China)

Author keywords

Chemical proteomics; Expression proteomics; Natural products; Target identification; Transcriptomics

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BAY 50 2369; BERBERINE; BIOTIN DERIVATIVE; CHLORAMPHENICOL; DOXORUBICIN; FUMAGILLIN; GLYCERALDEHYDE 3 PHOSPHATE; HYMENIALDISINE; LAF 389; LEPTOMYCIN B; MESSENGER RNA; METHIONYL AMINOPEPTIDASE; METHOTREXATE; NATURAL PRODUCT; OVALICIN; PACLITAXEL; PATEAMINE A; PHENETHYL ISOTHIOCYANATE; PHTHALASCIDIN; PROTEOME; PYRIMIDINONE DERIVATIVE; RETINOIC ACID; SAFRAMYCIN A; TACROLIMUS; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BIOTINYLATION; CARDIOTOXICITY; DNA LIBRARY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENOMICS; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HYPERSENSITIVITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOAFFINITY LABELING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TWO DIMENSIONAL ELECTROPHORESIS; TWO HYBRID SYSTEM;

EID: 41149173665     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200880002     Document Type: Review

References (107)

1. Newman, D. J., Cragg, G. M., Snader, K. M., Natural products as sources of new drugs over the period 1981-2002, J. Nat. Prod. 2003, 66, 1022-1037.
2. Newman, D. J., Cragg, G. M., Natural products as sources of new drugs over the last 25 years, J. Nat. Prod. 2007, 70, 461-477.
3. Tan, G., Gyllenhaal, C., Soejarto, D. D., Biodiversity as a source of anticancer drugs, Curr. Drug Targets 2006, 7, 265-277.
4. Burdine, L., Kodadek, T., Target identification in chemical genetics: The (often) missing link, Chem. Biol. 2004, 11, 593-597.
5. Rouhi, A. M., Rediscovering natural products, Chem. Eng. News 2003, 81, 77.
6. Ortholand, J. Y., Ganesan, A., Natural products and combinatorial chemistry: back to the future, Curr. Opin. Chem. Biol. 2004, 8, 271-280.
7. Blume-Jensen, P., Hunter, T., Oncogenic kinase signaling, Nature 2001, 411, 355-365.
8. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S. et al., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat. Med. 1996, 2, 561-566.
9. Bach, S., Knockaert, M., Reinhardt, J., Lozach, O. et al., Roscovitine targets, protein kinases and pyridoxal kinase, J. Biol. Chem. 2005, 280, 31208-31219.
10. Godl, K., Gruss, O. J., Eickhoff, J., Wissing, J. et al., Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling, Cancer Res. 2005, 65, 6919-6926.
11. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P. et al., An efficient proteomics method to identify the cellular targets of protein kinase inhibitors, Proc. Natl. Acad. Sci. USA 2003, 100, 15434-15439.
12. Meijer, L., Skaltsounis, A. L., Magiatis, P., Polychronopoulos, P. et al., GSK-3-selective inhibitors derived from Tyrian purple indirubins, Chem. Biol. 2003, 10, 1255-1266.
13. Wan, Y. Q., Hur, W. Y., Cho, C. Y., Liu, Y. et al., Synthesis and target identification of hymenialdisine analogs, Chem. Biol. 2004, 11, 247-259.
14. Schmitz, F. J., Gunasekera, S. P., Lakshmi, V., Tillekeratne, L. M. V., Marine natural-products - pyrrololactams from several sponges, J. Nat. Prod. 1985, 48, 47-53.
15. Walsh, D. P., Chang, Y. T., Chemical genetics, Chem. Rev. 2006, 106, 2476-2530.
16. Meijer, L., Thunnissen, A. M., White, A. W., Garnier, M. et al., Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent, Chem. Biol. 2000, 7, 51-63.
17. Northcote, P. T., Blunt, J. W., Munro, M. H. G., Pateamine - a potent cytotoxin from the New-Zealand marine sponge, Mycale Sp., Tetrahedron Lett. 1991, 32, 6411-6414.
18. Low, W. K., Dang, Y. J., Schneider-Poetsch, T., Shi, Z. G. et al., Inhibition of eukaryotic translation initiation by the marine natural product pateamine A, Mol. Cell 2005, 20, 709-722.
19. Gingras, A. C., Raught, B., Sonenberg, N., elF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation, Annu. Rev. Biochem. 1999, 68, 913-963.
20. Manske, R. H. F., The Alkaloids, Academic Press, New York 1983, p. v.
21. Ishiguro, K., Sakiyama, S., Takahashi, K., Arai, T., Mode of action of Saframycin-a, a novel heterocyclic quinone antibiotic - inhibition of Rna-synthesis in vivo and in vitro, Biochemistry 1978, 17, 2545-2550.
22. Martinez, E. J., Owa, T., Schreiber, S. L., Corey, E, J., Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743, Proc. Natl. Acad. Sci. USA 1999, 96, 3496-3501.
23. Xing, C. G., LaPorte, J. R., Barbay, J. K., Myers, A. G., Identification of GAPDH as a protein target of the saframycin antiproliferative agents, Proc. Natl. Acad. Sci. USA 2004, 101, 5862-5866.
24. Dastoor, Z., Dreyer, J. L., Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress, J. Cell Sci. 2001, 114, 1643-1653.
25. Hara, M. R., Agrawal, N., Kim, S. F., Cascio, M. B. et al., 5-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah 1 binding, Nat. Cell Biol. 2005, 7, 665-U640.
26. Sawa, A., Khan, A. A., Hester, L. D., Snyder, S. H., Glyceraldehyde-3-phosphate dehydrogenase: Nuclear translocation participates in neuronal and nonneuronal cell death, Proc. Natl. Acad. Sci. USA 1997, 94, 11669-11674. 27 Dorman, G., Prestwich, G. D., Using photolabile ligands in drug discovery and development, Trends Biotechnol. 2000, 18, 64-77.
27. Griffith, E. C., Su, Z., Turk, B. E., Chen, S. P. et al., Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin, Chem. Biol. 1997, 4, 461-471.
28. Sin, N., Meng, L. H., Wang, M. Q. W., Wen, J. J. et al., The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 1997, 94, 6099-6103.
29. Rodeschini, V., Boiteau, J. G., Van de Weghe, P., Tarnus, C., Eustache, J., MetAP-2 inhibitors based on the fumagillin structure. Side-chain modification and ring-substituted analogues, J. Org. Chem. 2004, 69, 357-373.
30. Uga, H., Kuramori, C., Ohta, A., Tsuboi, Y. et al., A new mechanism of methotrexate action revealed by target screening with affinity beads, Mol. Pharmacol. 2006, 70, 1832-1839.
31. Paschke, M., Phage display systems and their applications, Appl. Microbiol. Biotechnol. 2006, 70, 2-11.
32. Kimmel, A. R., Berger, S. L., Preparation of cCDNA and the generation of cDNA libraries - overview, Methods Enzymol. 1987, 152, 307-316.
33. Sche, P. P., McKenzie, K. M., White, J. D., Austin, D. J., Display cloning: functional identification of natural product receptors using cDNA-phage display, Chem. Biol. 1999, 6, 707-716.
34. Sche, P. P., McKenzie, K. M., White, J. D., Austin, D. J., Display cloning: functional identification of natural product receptors using cDNA-phage display, Chem. Biol. 2001, 8, 399-400.
35. McKenzie, K. M., Videlock, E. J., Splittgerber, U., Austin, D. J., Simultaneous identification of multiple protein targets by using complementary-DNA phage display and a natural-product-mimetic probe, Angew. Chem. Int. Ed. 2004, 43, 4052-4055.
36. Byrd, C. A., Bornmann, W., Erdjument-Bromage, H., Tempst, P. et al., Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide, Proc. Natl. Acad. Sci. USA 1999, 96, 5645-5650.
37. Rodi, D. J., Janes, R. W., Sanganee, H. J., Holton, R. A. et al., Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol binding protein, J. Mol. Biol. 1999, 285, 197-203.
38. Maundrell, K., Antonsson, B., Magnenat, E., Camps, M. et al., Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1, J. Biol. Chem. 1997, 272, 25238-25242.
39. Huizing, M. T., Keung, A. C. F., Rosing, H., Vanderkuij, V. et al., Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients, J. Clin. Oncol. 1993, 11, 2127-2135.
40. Boehmerle, W., Splittgerber, U., Lazarus, M. B., McKenzie, K. M. et al., Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism, Proc. Natl. Acad. Sci. USA 2006, 103, 18356-18361.
41. Makowski, L., Rodi, D. J., Genome-wide characterisation of the binding repertoire of small molecule drugs, Hum. Genomics 2003, 1, 41-51.
42. Piggott, A. M., Karuso, P., Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery, Comb. Chem. High Throughput Screen. 2004, 7, 607-630.
43. MacBeath, G., Schreiber, S. L., Printing proteins as microarrays for high-throughput function determination, Science 2000, 289, 1760-1763.
44. Kung, L.A., Snyder, M., Proteome chips for whole-organism assays, Nat. Rev. Mol. Cell Biol. 2006, 7, 617-622.
45. Birney, E., Andrews, D., Caccamo, M., Chen, Y. et al., Ensembl 2006. Nucleic Acids Res. 2006, 34, D556-D561.
46. Ziauddin, J., Sabatini, D. M., Microarrays of cells expressing defined cDNAs, Nature 2001, 411, 107-110.
47. Suzuki, Y., Sugano, S., Transcriptome analyses of human genes and applications for proteome analyses, Curr. Protein. Pept. Sci. 2006, 7, 147-163.
48. Bradner, J. E., McPherson, O. M., Mazitschek, R., Barnes-Seeman, D. et al., A robust small-molecule microarray platform for screening cell lysates, Chem. Biol. 2006, 13, 493-504.
49. Licitra, E. J., Liu, J. O., A three-hybrid system for detecting small ligand-protein receptor interactions, Proc. Natl. Acad. Sci. USA 1996, 93, 12817-12821.
50. He, Q. Y., Chiu, J. F., Proteomics in biomarker discovery and drug development, J. Cell. Biochem. 2003, 89, 868-886.
51. Lehmann, S., Bengtzen, S., Broberg, U., Paul, C., Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML, Leuk. Res. 2000, 24, 19-25.
52. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L. et al., Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia, Nature 1998, 391, 815-818.
53. Harris, M. N., Ozpolat, B., Abdi, F., Gu, S. et al., Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia, Blood 2004, 104, 1314-1323.
54. Wan, J. H., Wang, J. L., Cheng, H. P., Yu, Y. T. et al., Proteomic analysis of apoptosis initiation induced by all-trans retinoic acid in human acute promyelocytic leukemia cells, Electrophoresis 2001, 22, 3026-3037.
55. Wang, Y., He, Q. Y., Chen, H. M., Chiu, J. F., Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: Proteomic characterization, Exp. Cell Res. 2007, 313, 357-368.
56. Wu, N., Zhang, W., Yang, Y., Liang, Y. L. et al., Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration, Proteomics 2006, 6, 6095-6106.
57. Carpenter, B., MacKay, C., Alnabulsi, A., MacKay, M. et al., The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression, Biochim. Biophys. Acta 2006, 1765, 85-100.
58. Zhang, B. L., Zhang, Y. Q., Dagher, M. C., Shacter, E., Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis, Cancer Res. 2005, 65, 6054-6062.
59. Lee, K. H., Yim, E. K., Kim, C. J., Namkoong, S. E. et al., Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol. Oncol. 2005, 98, 45-53.
60. MacKeigan, J. P., Clements, C. M., Lich, J. D., Pope, R. M. et al., Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: Identification of RS/DJ-1 and RhoGDI alpha, Cancer Res. 2003, 63, 6928-6934.
61. Larsen, N. A., Al-Bassam, J., Wei, R. R., Harrison, S. C., Structural analysis of Bub3 interactions in the mitotic spindle checkpoint, Proc. Natl. Acad. Sci. USA 2007, 104, 1201-1206.
62. Sekito, A., Koide-Yoshida, S., Niki, T., Taira, T. et al., DJ-1 interacts with HIPK1 and affects H2O2-induced cell death, Free Radic. Res. 2006, 40, 155-165.
63. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O. et al., Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science 2003, 299, 256-259.
64. Tsuchiya, A., Tashiro, E., Yoshida, M., Imoto, M., Involvement of nuclear accumulation of heat shock protein 27 in leptomycin B-induced apoptosis in HeLa cells, J. Antibiot. 2005, 58, 810-816.
65. Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D. et al., Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region, Proc. Natl. Acad. Sci. USA 1999, 96, 9112-9117.
66. Viswanathan, S., Unlu, M., Minden, J. S., Two-dimensional difference gel electrophoresis, Nat. Protoc. 2006, 1, 1351-1358.
67. Unlu, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: a single gel method for detecting changes in protein extracts, Electrophoresis 1997, 18, 2071-2077.
68. Gong, L., Puri, M., Unlu, M., Young, M. et al., Drosophila ventral furrow morphogenesis: a proteomic analysis, Development 2004, 131, 643-656.
69. Neo, J. C., Rose, P., Ong, C. N., Chung, M. C., beta-Phenylethyl isothiocyanate mediated apoptosis: a proteomic investigation of early apoptotic protein changes, Proteomics 2005, 5, 1075-1082.
70. Towbin, H., Bair, K. W., DeCaprio, J. A., Eck, M. J. et al., Proteomics-based target identification - Bengamides as a new class of methionine aminopeptidase inhibitors, J. Biol. Chem. 2003, 278, 52964-52971.
71. Keeling, P. J., Doolittle, W. F., Methionine aminopeptidase-1: The MAP of the mitochondrion? Trends Biochem. Sci. 1996, 21, 285-286.
72. Bernier, S. G., Taghizadeh, N., Thompson, C. D., Westlin, W. F., Hannig, G., Methionine aminopeptidases type I and type II are essential to control cell proliferation, J. Cell. Biochem. 2005, 95, 1191-1203.
73. Bandow, J. E., Brotz, H., Leichert, L. I., Labischinski, H., Hecker, M., Proteomic approach to understanding antibiotic action, Antimicrob. Agents Chemother. 2003, 47, 948-955.
74. Washburn, M. P., Wolters, D., Yates, J. R., Large-scale analysis of the yeast proteome by multidimensional protein identification technology, Nat. Biotechnol. 2001, 19, 242-247.
75. Peng, J. M., Elias, J. E., Thoreen, C. C., Licklider, L. J., Gygi, S. P., Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: The yeast proteome, J. Proteome Res. 2003, 2, 43-50.
76. Delahunty, C., Yates, J. R., Protein identification using 2D-LC-MS/MS, Methods 2005, 35, 248-255.
77. Tan, Y. L., Goh, D., Ong, E. S., Investigation of differentially expressed proteins due to the inhibitory effects of berberine in human liver cancer cell line HepG2, Mol. Biosyst. 2006, 2, 250-258.
78. Dent, P., Yacoub, A., Fisher, P. B., Hagan, M. P., Grant, S., MAPK pathways in radiation responses, Oncogene 2003, 22, 5885-5896.
79. Tan, S., Seow, T. K., Liang, R. C. M. Y., Koh, S. et al., Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int. J. Cancer 2002, 98, 523-531.
80. Poirier, F., Joubert-Caron, R., Labas, V., Caron, M., Proteomic analysis of a lymphoma-derived cell line (DG75) following treatment with a demethylating drug: Modification of membrane-associated proteins, Proteomics 2003, 3, 1028-1036.
81. Kehrer, D. F. S., Soepenberg, O., Loos, W. J., Verweij, J., Sparreboom, A., Modulation of camptothecin analogs in the treatment of cancer: a review, Anti-Cancer Drugs 2001, 12, 89-105.
82. Yu, L. R., Johnson, M. D., Conrads, T. P., Morrison, R. S., Veenstra, T. D., Proteome analysis of camptothecin-treated cortical neurons using isotope-coded affinity tags, Electrophoresis 2002, 23, 3252-3252.
83. Yu, L. R., Conrads, T. P., Uo, T., Issaq, H. J. et al., Evaluation of the acid-cleavable isotope-coded affinity tag reagents: Application to camptothecin-treated cortical neurons, J. Proteome Res. 2004, 3, 469-477.
84. Canas, B., Lopez-Ferrer, D., Ramos-Fernandez, A., Camafeita, E., Calvo, E., Mass spectrometry technologies for proteomics, Brief. Funct. Genomic. Proteomic. 2006, 4, 295-320.
85. Wei, J., Sun, J., Yu, W., Jones, A. et al., Global proteome discovery using an online three-dimensional LC-MS/MS, J. Proteome Res. 2005, 4, 801-808.
86. Kim, Y. H., Cho, K., Yun, S. H., Kim, J. Y. et al., Analysis of aromatic catabolic pathways in Pseudomonas putida KT 2440 using a combined proteomic approach: 2-DE/MS and cleavable isotope-coded affinity tag analysis, Proteomics 2006, 6, 1301-1318.
87. Kubota, K., Wakabayashi, K., Matsuoka, T., Proteome analysis of secreted proteins during osteoclast differentiation using two different methods: two-dimensional electrophoresis and isotope-coded affinity tags analysis with two-dimensional chromatography, Proteomics 2003, 3, 616-626.
88. Schmidt, F., Dahlmann, B., Janek, K., Kloss, A. et al., Comprehensive quantitative proteome analysis of 20S proteasome subtypes from rat liver by isotope coded affinity tag and 2-D gel-based approaches, Proteomics 2006, 6, 4622-4632.
89. Schmidt, F., Donahoe, S., Hagens, K., Mattow, J. et al., Complementary analysis of the Mycobacterium tuberculosis proteome by two-dimensional electrophoresis and isotope-coded affinity tag technology, Mol. Cell. Proteomics 2004, 3, 24-42.
90. Butte, A., The use and analysis of microarray data, Nat. Rev. Drug Discov. 2002, 1, 951-960.
91. Dechering, K. J., The transcriptome's drugable frequenters, Drug Discov. Today 2005, 10, 857-864.
92. Draghici, S., Khatri, P., Eklund, A. C., Szallasi, Z., Reliability and reproducibility issues in DNA microarray measurements, Trends Genet. 2006, 22, 101-109.
93. Jaluria, P., Konstantopoulos, K., Betenbaugh, M., Shiloach, J., A perspective on microarrays: current applications, pitfalls, and potential uses, Microb. Cell Fact. 2007, 6, 4.
94. Rhodius, V. A., LaRossa, R. A., Uses and pitfalls of microarrays for studying transcriptional regulation, Curr. Opin. Microbiol. 2003, 6, 114-119.
95. Hegde, P. S., White, I. R., Debouck, C., Interplay of transcriptomics and proteomics, Curr. Opin. Biotechnol. 2003, 14, 647-651.
96. Wang, D., Jensen, R., Gendeh, G., Williams, K., Pallavicini, M. G., Proteome and transcriptome analysis of retinoic acid-induced differentiation of human acute promyelocytic leukemia cells, NB4, J. Proteome Res. 2004, 3, 627-635.
97. Zheng, P. Z., Wang, K. K., Zhang, Q. Y., Huang, Q. H. et al., Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia, Proc. Natl. Acad. Sci. USA 2005, 102, 7653-7658.
98. Kuo, C. C., Kuo, C. W., Liang, C. M., Liang, S. M., A transcriptomic and proteomic analysis of the effect of CpG-ODN on human THP-1 monocytic leukemia cells, Proteomics 2005, 5, 894-906.
99. Takeda, K., Akira, S., Roles of Toll-like receptors in innate immune responses, Genes Cells 2001, 6, 733-742.
100. Anderson, L., Seilhamer, J., A comparison of selected mRNA and protein abundances in human liver, Electrophoresis 1997, 18, 533-537.
101. Fessler, M. B., Malcolm, K. C., Duncan, M. W., Worthen, G. S., A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase, J. Biol. Chem. 2002, 277, 31291-31302.
102. Gygi, S. P., Rochon, Y., Franza, B. R., Aebersold, R., Correlation between protein and mRNA abundance in yeast, Mol. Cell. Biol. 1999, 19, 1720-1730.
103. Scheurer, S. B., Rybak, J. N., Rosli, C., Neri, D., Elia, G., Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study, Proteomics 2004, 4, 1737-1760.
104. Gallagher, W. M., Lynch, I., Allen, L. T., Miller, I. et al., Molecular basis of cell-biomaterial interaction: insights gained from transcriptomic and proteomic studies, Biomaterials 2006, 27, 5871-5882.
105. Lee, J. K., Bussey, K. J., Gwadry, F. G., Reinhold, W. et al., Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells, Genome Biol. 2003, 4, R82.
106. He, L., Orr, G. A., Horwitz, S. B., Novel molecules that interact with microtubules and have functional activity similar to Taxol™, Drug Discovery Today 2001, 6, 1153-1164.
107. Sugimura, M., Sagae, S., Ishioka, S., Nishioka, Y., Tsukada, K., Kudo, R., Mechanisms of Paclitaxel-induced apoptosis in an ovarian cancer cell line and its Paclitaxel-resistant clone, Oncology 2004, 66, 53-61.